Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesus San Miguel*, Katja Weisel, Philippe Moreau, Martha Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Andrew Belch, Antonio Palumbo, Stephen Schey, Pieter SonneveldXin Yu, Lars Sternas, Christian Jacques, Mohamed Zaki, Meletios Dimopoulos

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    686 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.